Platelet preservation composition comprising a short to ultra-short acting antiplatelet agent and anticoagulant with hemoglobin

• US 8,129,104 B2
• Filed: 05/11/2009
• Issued: 03/06/2012
• Est. Priority Date: 01/12/2005
• Status: Active Grant

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec Transfusion LLC
• Inventors: Sehgal, Lakshman R., Mousa, Shaker
• Primary Examiner(s): SAUCIER, SANDRA E
• Application Number:
  US12/463,495
• Publication Number:
  US 20090253115A1
• Time in Patent Office: 1,030 Days
• Field of Search: None
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Abstract

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Claims

1. A platelet preservation composition, comprising:

a) a short-to-ultra-short acting antiplatelet agent;

b) a short-to-ultra-short acting anticoagulant; and

c) a hemoglobin-based oxygen carrier;

wherein said composition is capable of extending the shelf-life of a platelet.

2. The composition of claim 1, wherein said antiplatelet agent is capable of reversing blocking platelet activation and/or aggregation by blocking sites on the platelet surface.

3. The composition of claim 1, wherein said antiplatelet agent is capable of binding to, or associating with a GPIIb/IIIa receptor site.

4. The composition of claim 1, wherein said antiplatelet agent is selected from the group consisting of DUP 728, XJ 757, XR 299, eptifibatide, orbofiban, xemilofiban, lamifiban, tirofiban, and mixtures thereof.

5. The composition of claim 1, wherein said antiplatelet agent is selected from the group consisting of linear and cyclic RGD-containing peptides.

6. The composition of claim 5, wherein said linear and cyclic RGD-containing peptides are conjugated to a nitric oxide donor.

7. The composition of claim 1, wherein said antiplatelet agent is a pharmaceutically acceptable antiplatelet agent and has a circulating half-life of inhibition of about less than 4 hours.

8. The composition of claim 1, wherein said antiplatelet agent comprises about 0.001 mg to about 5 of a GPIIb/IIIa inhibitor.

9. The composition of claim 1, wherein said anticoagulant is a compound that reversibly inhibits factor Xa, or factor IIa, or both.

10. The composition of claim 9, wherein said anticoagulant is an Xa inhibitor with a circulating half-life of less than 4 hours.

11. The composition of claim 10, wherein said anticoagulant is selected from the group consisting of DX-9065a, BX-80783 and RPR-120844.

12. The composition of claim 10, wherein said anticoagulant is a factor IIa inhibitor selected from the group consisting of hirudin, hirulog, melagatran, and combinations thereof.

13. The composition of claim 1, wherein said anticoagulant is a pharmaceutically acceptable anticoagulant and is a combination of at least one IIa inhibitor with a circulating half-life of less than 4 hours and at least one Xa inhibitor with a circulating half-life of less than 4 hours.

14. The composition of claim 1, wherein said antiplatelet agent is a compound that binds to or associates with GPIIb/IIIa sites, and wherein the anticoagulant is a factor Xa inhibitor, a factor IIa inhibitor, or a combination of both.

15. The composition of claim 1, wherein said hemoglobin-based oxygen carrier is substantially free of red cell membrane contaminants.

16. The composition of claim 1, further comprising a anti-microbial agent selected from the group consisting of:

penicillin, monobactam, cephalosporins, carbapenems, vancomycin, isoniazid, ethambutol, aminoglycosides, tetracycline, chloramphenicol, macrolides, rifamycin, quinolone, fluoroquinolone, sulfonamides, polyene antibiotics, imidazole, triazole, griseofulvin and combinations thereof.

17. The composition of claim 5, wherein said antiplatelet agent is a RGD-containing peptides.

18. The composition of claim 17, wherein said antiplatelet agent is DUP 728.